Product Images Phenytoin Sodium

The administration of intravenous Phenytoin Sodium Injection should not exceed certain rates to avoid cardiovascular risk. The recommended rates are 50 mg per minute in adults and 1-3 mg/kg/min (or 50 mg per minute, whichever is slower) in pediatric patients. Careful cardiac monitoring is required during and after the administration of this drug. Even at or below the recommended infusion rate, there is a risk of severe hypotension and cardiac arrhythmias. Dosage may need to be reduced or discontinued if necessary. See Dosage and Administration (2.1) and Warnings and Precautions (5.1) for more information.*

This document is a list of drugs that can be affected by the presence of phenytoin in the body. It includes several examples of drugs whose efficacy is impaired by phenytoin, such as antineoplastic agents, azoles, and neuromuscular blocking agents. The list also includes drugs whose level is decreased by phenytoin, such as antiepileptic drugs, antilipidemic agents, and antiviral agents. Furthermore, it highlights interactions with other medications such as calcium channel blockers, corticosteroids, and warfarin, among others. The document provides recommendations for the prevention or management of adverse interactions between phenytoin and other drugs.*

This is a useful description of drugs that interact with the medication phenytoin. The text lists various types of drugs, including antiepileptic, antineoplastic, and antidepressant agents, as well as other medications like sulfonamides and drugs that reduce gastric acid. The categories include drugs that may increase or decrease phenytoin serum levels, or may have varying effects. Several specific examples of drugs that affect phenytoin levels are also included.*

Phenytoin Sodium Injection should not be administered at a rate faster than the recommended rate, to avoid the risk of severe hypotension and cardiac arrhythmias. The recommended infusion rate is 50 mg per minute in adults and 1 to 3 mg/kg/min (or 50 mg per minute, whichever is slower) in children. Close cardiac monitoring is required during and after intravenous administration. Cardiovascular complications may occur even at or below the recommended infusion rate. Administration may need to be stopped or slowed down if necessary. This information is available in the Dosage and Administration and Warnings Precautions sections.*

This is a description of a medication in a single dose vial with a strength of 50mg/mt for IV or IM use. The name of the medication is not provided as it is not available in the given text.*